ABIOMED is a healthcare equipment & supplies business based in the US. ABIOMED shares (ABMD) are listed on the NASDAQ and all prices are listed in US Dollars. ABIOMED employs 2,003 staff and has a trailing 12-month revenue of around $1.1 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $351.42 |
| 200-day moving average | $291.67 |
| Wall St. target price | $363.00 |
| PE ratio | 65.3551 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $5.83 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing ABIOMED stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ABIOMED's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ABIOMED's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 65x. In other words, ABIOMED shares trade at around 65x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
ABIOMED's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.75. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ABIOMED's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
ABIOMED's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $274.2 million.
The EBITDA is a measure of a ABIOMED's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.1 billion |
|---|---|
| Operating margin TTM | 22.96% |
| Gross profit TTM | $843.6 million |
| Return on assets TTM | 9.55% |
| Return on equity TTM | 18.24% |
| Profit margin | 24.84% |
| Book value | $34.09 |
| Market Capitalization | $17.2 billion |
TTM: trailing 12 months
We're not expecting ABIOMED to pay a dividend over the next 12 months.
ABIOMED's shares were split on a 2:1 basis on 1 October 2000 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your ABIOMED shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ABIOMED shares which in turn could have impacted ABIOMED's share price.
Over the last 12 months, ABIOMED's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ABIOMED's is 1.3976. This would suggest that ABIOMED's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2. 5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5. 0, Impella LD, and Impella 5.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.